Sorafenib inhibits multiple receptor tyrosine kinases such as the VEGFR and PDGFR signaling pathways and has been the first-line drug in the treatment of advanced HCC for a long time [2]. This evidence concerns the gene KDR and hepatocellular carcinoma.